Comparative treatment efficiency of adipose and bone marrow derived allogenic mesenchymal stem cell transplantation in mouse models of liver fibrosis

Nguyen, Nam Hoai; Lê, Thạch Ngọc; Quang, Huy; Ngo, Dat Quoc; Le, Huy Minh; Truong, Nhung Hai

doi:10.15419/bmrat.v4i06.179

Cited by 5 publications

(2 citation statements)

References 21 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Первые сообщения об экспериментальном использовании МСК, выделенных из жировой ткани, в модели фиброза печени появились сравнительно недавно. В 2017 г. две группы исследователей сообщили о сравнимом противовоспалительном и антифибротическом эффекте МСК костного мозга и жировой ткани в модели CCl4индуцированного фиброза печени у мышей [7] и крыс [4], а также о более выраженном антипролиферативном и проапоптогенном эффекте МСК жировой ткани в отношении звездчатых клеток печени [4].…”

Section: результаты и обсуждениеunclassified

First experience in usage of lipoaspirate-derived mesenchymal stromal cells in combined treatment of the patients with liver cirrhosis

Zheltova

Shevela

Meledina

et al. 2022

Russian Journal of Immunology

View full text Add to dashboard Cite

Liver cirrhosis (LC) is a serious problem with respect to drug therapy. Certain promises are associated with development of stem cell-based technologies, in particular, mesenchymal stromal cells (MSCs). Over recent years, a significant interest was drawn to the usage of MSCs isolated from adipose tissue, which have a number of advantages over bone marrow MSCs. The aim of this study was to evaluate safety and tolerability of transplantation of autologous MSCs derived from adipose tissue (lipoaspirate) when treating the patients with LC of different origin. The study group consisted of 12 patients (4 men and 8 women), aged 33 to 67 years. In six patients, development of LC was due to viral hepatitis; in other subjects it was caused by non-viral factors, including toxic effects (n = 3), primary biliary cirrhosis (n = 2) and cryptogenic cirrhosis (n = 1). The LC severity assessed by the Child-Pugh scale corresponded to class A (6 cases) or class B (6 patients). The MELD scores varied from 8 to 11. All patients were injected once with autologous MSCs (a mean of 12.94 106, 11.3 to 16.0 106) obtained by culturing the lipoaspirate cells for 14 days. Lipoaspiration and injection of MSCs were not accompanied by development of side effects, or serious adverse events. Analysis of clinical efficacy, carried out 6-12 months after therapy, made it possible to distinguish two subgroups: responders to the therapy (subgroup 1, n = 6) and non-responders (subgroup 2, n = 6). In subgroup 1, the MELD score was found to be decreased in 4 cases, and did not change in 2 patients. In contrast, the MELD score increased in the patients from subgroup 2. Both subgroups did not differ in etiology and severity of LC, or concomitant pathology (COVID-19). Positive dynamics in subgroup 1 was revealed for the signs of hepatocellular insufficiency (n = 1), cytolysis (n = 2) and cholestasis (n = 1). In two patients with MELD score stabilization, the scores reached the reference values. After MSC therapy, the majority of patients (8/12) underwent a new coronavirus infection, and the COVID incidence rate was similar in groups with or without response to MSC therapy (4 patients in each group). The results of the study suggest the safety of using MSCs isolated from the adipose tissue of patients with liver cirrhosis, and the perspectives of such approach in order to stabilize or improve liver function.

show abstract

Section: результаты и обсуждениеunclassified

First experience in usage of lipoaspirate-derived mesenchymal stromal cells in combined treatment of the patients with liver cirrhosis

Zheltova

Shevela

Meledina

et al. 2022

Russian Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Comparatives studies between BMMSCs and adipose tissue-derived mesenchymal stem cells (ADSCs) demonstrate that both sources are effective in liver fibrosis treatment, but ADSCs promote a higher inhibition of proliferation, activation, and apoptosis of HSCs, in addition to a better AST/ALT ratio. These results, combined with the facility of obtaining these cells from adipose tissue compared to bone marrow, suggest that ADSCs could be a great alternative source for therapy [134,135].…”

Section: Cell Types Used For the Inhibition Of Liver Fibrosismentioning

confidence: 99%

Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview

Pinheiro

Dias

Silva

et al. 2019

Cells

View full text Add to dashboard Cite

Fibrosis is a common feature in most pathogenetic processes in the liver, and usually results from a chronic insult that depletes the regenerative capacity of hepatocytes and activates multiple inflammatory pathways, recruiting resident and circulating immune cells, endothelial cells, non-parenchymal hepatic stellate cells, and fibroblasts, which become activated and lead to excessive extracellular matrix accumulation. The ongoing development of liver fibrosis results in a clinically silent and progressive loss of hepatocyte function, demanding the constant need for liver transplantation in clinical practice, and motivating the search for other treatments as the chances of obtaining compatible viable livers become scarcer. Although initially cell therapy has emerged as a plausible alternative to organ transplantation, many factors still challenge the establishment of this technique as a main or even additional therapeutic tool. Herein, the authors discuss the most recent advances and point out the corners and some controversies over several protocols and models that have shown promising results as potential candidates for cell therapy for liver fibrosis, presenting the respective mechanisms proposed for liver regeneration in each case.

show abstract

Recruitment of macrophages and bone marrow stem cells to regenerating liver promoted by sodium phthalhydrazide in mice

Данилова

Yushkov

Казакова

et al. 2019

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Comparative treatment efficiency of adipose and bone marrow derived allogenic mesenchymal stem cell transplantation in mouse models of liver fibrosis

Cited by 5 publications

References 21 publications

First experience in usage of lipoaspirate-derived mesenchymal stromal cells in combined treatment of the patients with liver cirrhosis

First experience in usage of lipoaspirate-derived mesenchymal stromal cells in combined treatment of the patients with liver cirrhosis

Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview

Recruitment of macrophages and bone marrow stem cells to regenerating liver promoted by sodium phthalhydrazide in mice

Contact Info

Product

Resources

About